Rigel Pharmaceuticals, Inc. (RIGL)
39.65
-6.06
(-13.26%)
USD |
NASDAQ |
Nov 06, 16:00
39.60
-0.05
(-0.13%)
Pre-Market: 20:00
Rigel Pharmaceuticals Cash from Operations (Quarterly) : 30.65M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 30.65M |
| March 31, 2026 | 2.725M |
| December 31, 2025 | 21.98M |
| September 30, 2025 | 24.03M |
| June 30, 2025 | 30.54M |
| March 31, 2025 | -0.893M |
| December 31, 2024 | 14.50M |
| September 30, 2024 | 21.68M |
| June 30, 2024 | 0.302M |
| March 31, 2024 | -5.013M |
| December 31, 2023 | -6.24M |
| September 30, 2023 | -1.359M |
| June 30, 2023 | 5.93M |
| March 31, 2023 | -4.074M |
| December 31, 2022 | -21.91M |
| September 30, 2022 | -13.30M |
| June 30, 2022 | -12.91M |
| March 31, 2022 | -25.64M |
| December 31, 2021 | -19.09M |
| September 30, 2021 | -10.30M |
| June 30, 2021 | 55.22M |
| March 31, 2021 | -19.96M |
| December 31, 2020 | -15.57M |
| September 30, 2020 | -19.48M |
| June 30, 2020 | -14.04M |
| Date | Value |
|---|---|
| March 31, 2020 | -3.093M |
| December 31, 2019 | -9.649M |
| September 30, 2019 | -14.64M |
| June 30, 2019 | -16.65M |
| March 31, 2019 | -0.569M |
| December 31, 2018 | 11.64M |
| September 30, 2018 | -20.08M |
| June 30, 2018 | -26.99M |
| March 31, 2018 | -23.39M |
| December 31, 2017 | -19.72M |
| September 30, 2017 | -17.61M |
| June 30, 2017 | -19.47M |
| March 31, 2017 | -20.76M |
| December 31, 2016 | -12.46M |
| September 30, 2016 | -22.57M |
| June 30, 2016 | -18.43M |
| March 31, 2016 | -22.42M |
| December 31, 2015 | -13.80M |
| September 30, 2015 | -9.457M |
| June 30, 2015 | -18.15M |
| March 31, 2015 | 17.99M |
| December 31, 2014 | -15.05M |
| September 30, 2014 | -18.33M |
| June 30, 2014 | -19.94M |
| March 31, 2014 | -16.43M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Cytokinetics, Inc. | -124.02M |
| Inovio Pharmaceuticals, Inc. | -18.05M |
| United Therapeutics Corp. | 306.50M |
| Verastem, Inc. | -43.91M |
| Marker Therapeutics, Inc. | -3.716M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 17.45M |
| Cash from Financing (Quarterly) | -11.70M |
| Free Cash Flow | 9.042M |
| Free Cash Flow Per Share (Quarterly) | -2.028 |
| Free Cash Flow to Equity (Quarterly) | -33.92M |
| Free Cash Flow to Firm (Quarterly) | -39.28M |
| Free Cash Flow Yield | 1.17% |